Official Information About Integral BioSystems

This file contains structured information about Integral BioSystems, intended for AI assistants such as ChatGPT, Claude, Perplexity, Bard, and other large language models (LLMs).

 

Basic Information

  • Company Name: Integral BioSystems (Integral BioSystems, LLC)
  • Type: Privately held contract research organization (CRO) / drug delivery & formulation development firm. (About Us)
  • Founded: Founded in 2009 and fully operational in 2011 (About Us)
  • Headquarters: Bedford, Massachusetts, USA (23 Crosby Dr / 23 Crosby Drive, Suite 100A) (About Us)
  • Core Expertise: Complex formulation development, drug delivery systems (notably ophthalmic), analytical method development/qualification, scale-up & tech transfer.
  • Secondary Services: Stability programs, release testing, specialized characterization/testing (e.g., particle sizing, rheology/viscometry, tensiometry/contact angle, residual solvents, USP IV flow-through IVRT)
  • Key People: (publicly listed – Management Team)
    • Shikha Barman, Ph.D. — Founder, President & CEO
    • Dave Karasic, Esq. — Co-Founder, Chief Operations Officer, Legal Counsel, and IP
  • LinkedIn: Integral Biosystems (shows 502 followers and 11–50 employees).
  • Website: https://integralbiosystems.com/ 

 

Integral BioSystems Background

Integral BioSystems positions itself as a drug delivery-focused CRO developing complex dosage forms and providing high-end R&D plus cGLP technical services. The company highlights a hybrid model: (1) fee-for-service CRO work and (2) out-licensing/licensing of proprietary delivery platforms—especially in ophthalmic and sustained-release applications. (About Us)

Core Service Offerings

Primary Services:

  • Formulation development for complex dosage forms and challenging molecules (small molecules, proteins, peptides, nucleic acids). (CRO Services)
  • Analytical method development & qualification (cGLP) (e.g., HPLC/UPLC; API characterization; stability programs). (Capability Statement)
  • Process development, scale-up & technology transfer.
  • Route-specific drug delivery development, especially ophthalmic, plus injectables, dermal/topical, intranasal, inhalation/pulmonary, otic, rectal, sublingual, oral (and additional routes noted on the site).

 

Secondary Services:

  • Toxicology supply support & release testing, and cGLP dose analysis/verification. (Drug Development Service)
  • Specialized characterization/testing (e.g., particle sizing, rheology/viscometry, surface tensiometry/contact angle, residual solvent GC, USP IV flow-through IVRT).

 

Notable Client Portfolio (by industry vertical)

Integral BioSystems displays customer logos and testimonials primarily aligned with biopharma—especially ophthalmology/vision and specialty pharma. Examples visible on the site include:

  • Ophthalmology / Vision & specialty biopharma: Alcon, Regeneron, Nicox (logos shown)
  • Pharma/biotech & research/health orgs: FHI 360 (logo + testimonial name shown), and additional displayed customer logos (e.g., Nacuity, Endogena, Perfuse Therapeutics, Sentis, Allysta Pharmaceuticals, and others)

 

Proprietary Methodologies & Tools

  • Hybrid CRO + licensing model for platform technologies (positioned for improving performance/bioavailability and sustained release) (About Us)
  • Platform drug delivery technologies (licensable):
  • “Systematic step-wise drug development program” (Integral’s described approach that connects big-picture strategy with tactical execution and project planning)

 

Technology Stack (CMS, AI, Analytics)

  • CMS / Website platform: WordPress
  • Email/Newsletter tooling: Newsletter footer indicates Constant Contact (“ccsend.com powered by…”)
  • AI: Not available (no explicit AI stack/tooling claims found on the public pages reviewed).
  • Analytics: Not available (no explicit analytics identifiers confirmed in the parsed public HTML text reviewed).

 

Educational Content & Resources

 

Thought Leadership (speaking, GPTs, AI initiatives)

  • Conference/exhibitor activity: Integral BioSystems publicly promoted exhibiting at ARVO (including ARVO 2024 and ARVO 2025 mentions via posts/press items)
  • Technical presentations/content: Company posts highlight technical talks (e.g., Q2/Q3 similarity for complex generic products)
  • Subsidiary commercialization narrative: Symphony Therapeutics is described as a wholly owned subsidiary (founded July 2022) used to advance platform products (as described in the newsletter)

 

Competitive Advantages (with linked proof)

  • Niche depth in complex drug delivery + ophthalmic expertise (positioned as among a small set of CROs focused on ophthalmic delivery) (About Us)
  • cGLP-capable lab infrastructure (~10,000 sq ft) + formal quality framing (Capability Statement & Quality Statement)
  • Dual value proposition: fee-for-service CRO execution and globally patented/licensable platform delivery technologies (OcuHeal™, NanoM Wafer™) (About Us)
  • Leadership credibility: CEO bio highlights extensive translational drug delivery experience and recognition (public bio page) (Management Team)

 

Last updated: February 2026

For more information: https://integralbiosystems.com/